Oct 9
|
Vaxart Inc (VXRT) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Advances
|
Sep 30
|
Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
|
Aug 28
|
Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia
|
Aug 15
|
Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside
|
Aug 11
|
Vaxart Second Quarter 2024 Earnings: Misses Expectations
|
Jun 22
|
While institutions invested in Vaxart, Inc. (NASDAQ:VXRT) benefited from last week's 23% gain, retail investors stood to gain the most
|
Jun 14
|
Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering
|
Jun 13
|
Vaxart Announces $40 Million Underwritten Offering of Common Stock
|
Jun 13
|
Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
|
May 14
|
Q1 2024 Vaxart Inc Earnings Call
|
May 14
|
Vaxart Inc (VXRT) Q1 2024 Earnings Call Transcript Highlights: Promising Developments and ...
|
May 13
|
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
|
May 7
|
Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13
|
Apr 30
|
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
|
Apr 9
|
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
|
Mar 27
|
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
|
Mar 20
|
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Mar 17
|
Estimating The Intrinsic Value Of Vaxart, Inc. (NASDAQ:VXRT)
|
Mar 15
|
Vaxart, Inc. (NASDAQ:VXRT) Q4 2023 Earnings Call Transcript
|
Mar 15
|
Q4 2023 Vaxart Inc Earnings Call
|